- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.12.24 | Vifor Pharma offers £23m to NHS to resolve CMA investigation | ||
| 11.12.24 | Er-Kim and Ascendis' endocrine therapy agreement extended in Eurasia | ||
| 11.12.24 | The Innovations Shoring Up Clinical Supply Chain Integrity in the Age of Advanced Therapies | ||
| 11.12.24 | Overcoming the first hurdles: Navigating early phase challenges for biotechs | ||
| 11.12.24 | Relation-GSK to drive fibrotic and osteoarthritis developments | ||
| 11.12.24 | Better prevention and treatment options needed for genital herpes, WHO says | ||
| 11.12.24 | Lilly's £279m bet aims to boost UK life sciences sector | ||
| 11.12.24 | ASH 2024: J&J's Tecvayli shows promise in transplant-eligible NDMM patient | ||
| 11.12.24 | Dr Myles Greenberg becomes president and CEO of InCarda Therapeutics | ||
| 10.12.24 | ASH 2024: Regeneron's Ordspono faces challenges, but positive results signal hope | ||
| 10.12.24 | New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III | ||
| 10.12.24 | EMA validates Chiesi and Protalix's dose variation for Fabry disease | ||
| 10.12.24 | RSV prophylactic market to reach $6.2bn in 8MM by 2030 | ||
| 10.12.24 | Santhera's DMD therapy Agamree approved for NHS use after new price deal | ||
| 10.12.24 | Seres' SER-155 gains breakthrough status for BSIs reduction | ||
| 10.12.24 | FDA to review GSK's Nucala for COPD | ||
| 09.12.24 | Daiichi Sankyo secures breakthrough designation for NSCLC treatment | ||
| 09.12.24 | Citryll gains Series B funds to develop NET-targeting antibody | ||
| 09.12.24 | Bringing Engineering to a New Level: ZETA's Integrated Approach | ||
| 09.12.24 | Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill | ||
| 09.12.24 | Novo Holdings' acquisition of Catalent gains EC approval | ||
| 09.12.24 | Innovative Buffer Management Solutions: ZETA's Modular Buffer Inline Conditioning System | ||
| 09.12.24 | Priority FDA review given to AstraZeneca's Imfinzi sBLA for MIBC | ||
| 06.12.24 | FDA shares new draft guidance for accelerated approval | ||
| 06.12.24 | New study finds obesity costs US industry $347bn a year |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
